Lewis Silkin’s Hong Kong-based intellectual property (IP) head for Asia Pacific, David Swain, has left the firm to go in-house.
Swain is now the general counsel of Hong Kong-listed bio-pharmaceutical company, Essex Bio-Technology, according to an update on his LinkedIn profile.
